MultiOmics in Precision Medicine, a Precision Medicine Leaders’ Summit event
Olink Proteomics sponsored Panel Discussion:
“From Micro to Macro: Proteomics Driving insights from Cellular to Population Scale”
Dr. Genevieve M. Boland, MD, PhD, FACS
Associate Professor of Surgery at Harvard Medical School, Section Head of Melanoma/Sarcoma Surgery, and Surgical Director of the Termeer Center for Targeted Therapies at the Massachusetts General Hospital.
Her primary clinical focus is on melanoma and cutaneous oncology. She undertook combined MD/PhD training, completing a PhD in Cell and Tissue Engineering at the National Institutes of Health focusing on signaling pathways in adult, human mesenchymal stem cells. She graduated cum laude from Thomas Jefferson University as a member of the Alpha Omega Alpha medical honor society and completed her general surgical training at Massachusetts General Hospital. Following this, she completed a clinical fellowship in Complex General Surgical Oncology and a combined research fellowship at the University of Texas MD Anderson Cancer Center. She is focused on the clinical management of skin cancer patients. She is board certified in General Surgery and Complex General Surgical Oncology, and she is a Fellow of the American College of Surgeons. Dr. Boland has received research support from many groups including the American Surgical Association Foundation Fellowship, the Association of Women Surgeons Research Fellowship, the Harvard Catalyst Medical Research Investigator Training Award, the Karin Grunebaum Cancer Foundation Fellowship, the Society of Surgical Oncology, the Melanoma Research Foundation Breakthrough Consortium, the National Institutes of Health, and the Department of Defense. She is Director of the Surgical Oncology Research Laboratories and Director of the Therapeutic Intralesional Program where she is building a portfolio of direct-to-tumor therapies across multiple tumor types. She is also an Associate Member of the Broad Institute of MIT and Harvard. Her laboratory is currently focused on molecular profiling of melanoma, characterization of molecular and immunological changes that occur during immunotherapy, and the identification of circulating biomarkers of cancer.
Dr. Benjamin Sun, MD, PhD
Associate Scientific Director at Biogen.
Associate Scientific Director at Biogen, focusing on translating multi-omics and digital health data to better understand disease and drug targeting. He received his medical training, bachelor’s degree and PhD in statistical genomics through the MD-PhD programme at the University of Cambridge, where he graduated with distinction and also serves as a visiting fellow there. He previously worked as a physician at the Royal Free hospital in London before joining Biogen. As a physician scientist, Dr Sun is interested in integrating multi-omics, electronic health data and modern machine learning approaches in the context of health and drug development. His research has featured in various prestigious journals such as Nature.
Moderator: Evan Mills
Vice President Global Strategic Accounts, Olink Proteomics
Evan has been representing innovative technologies with the goal of putting best-in-class research tools in the hands of the world’s top scientists to advance our understanding of health and disease for the past 13 years. Previous Scientific experiences include Molecular and Developmental Biology at Wesleyan University, Neuroscience at Yale University and Oncology research at Curagen corp.
In his current role at Olink, Evan leads a global team supporting a number of Strategically important relationships.